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Abstract
Background—Although used as criterion for early drain removal, postoperative day (POD) 1 
drain fluid amylase (DFA) ≤ 5000 U/L has low negative predictive value for clinically relevant 
postoperative pancreatic fistula (CR-POPF). It was hypothesized that POD3 DFA ≤ 350 could 
provide further information to guide early drain removal.
Methods—Data from a pancreas surgery consortium database for pancreatoduodenectomy and 
distal pancreatectomy patients were analyzed retrospectively. Those patients without drains or 
POD 1 and 3 DFA data were excluded. Patients with POD1 DFA ≤ 5000 were divided into groups 
based on POD3 DFA: Group A (≤ 350) and Group B (> 350). Operative characteristics and 60-day 
outcomes were compared using chi-square test.
Results—Among 687 patients in the database, all data were available for 380. Fifty-five (14.5%) 
had a POD1 DFA > 5000. Among 325 with POD1 DFA ≤ 5000, 254 (78.2%) were in Group A and 
71 (21.8%) in Group B. Complications (35 (49.3%) vs 87 (34.4%); p = 0.021) and CR-POPF (13 
(18.3%) vs 10 (3.9%); p < 0.001) were more frequent in Group B.
Conclusions—In patients with POD1 DFA ≤ 5000, POD3 DFA ≤ 350 may be a practical test to 
guide safe early drain removal. Further prospective testing may be useful.
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Introduction
Many surgeons use intraperitoneal drains after pancreatectomy to allow for early 
identification, and mitigation, of complications associated with clinically relevant 
postoperative pancreatic fistulae (CR-POPF). However, it has been suggested that leaving 
drains in patients at lower risk of developing CR-POPF can be detrimental.1 Bassi and 
colleagues demonstrated that early drain removal improved outcomes in patients with a 
postoperative day 1 drain fluid amylase (POD1 DFA) ≤ 5000 U/L.2 They randomized low 
risk patients into early (POD3) and late (≥ POD5) drain removal. Early drain removal was 
associated with lower rates of pancreatic fistula, abdominal complications, and a shorter 
length of stay (LOS).1
Patients with a POD1 DFA > 5000 U/L have a 70% incidence of CR-POPF.3, 4 However, 
POD1 DFA ≤ 5000 U/L does not reliably predict the absence of CR-POPF.3 Previous reports 
have identified a POD1 DFA cutoff of < 90 U/L as having the highest negative predictive 
value (98.2%) for pancreatic fistula.5 This uncertainty has discouraged some surgeons from 
removing drains early in the postoperative course. A meta-analysis by Giglio et al. included 
13 studies (n = 4416 patients) with the aim of defining the accuracy of drain amylase values 
in predicting postoperative pancreatic fistula (POPF).3 The authors determined that the 
probability of developing a CR-POPF if POD1 drain amylase is < 100 U/L is 3%. However, 
only 34% of patients had a POD1 drain amylase < 100 U/L. The authors suggested that a 
cut-off value of 350 U/L may be more clinically useful since 50% of patients were found to 
have values in this range and the incidence of CR-POPF was only 4%.
In addition to POD1, a second analysis of DFA later in the postoperative course may add 
additional useful data to predict an evolving or subsequent CR-POPF. Partelli et al. 
demonstrated that POD5 DFA > 200 U/L had a sensitivity of 90% and a specificity of 83% 
in predicting POPF.4 Okano and colleagues calculated drain amylase output as the product 
of DFA concentration and the volume of fluid. The ratio of POD3/POD1 drain amylase 
output was lower in those patients that did not develop a CR-POPF.6
It is important to note that drains were not removed on POD1 in the only randomized 
prospective trial of early drain removal.1 Drains were removed on POD3-5 if additional 
criteria were met. If the appearance of the drain fluid suggested a pancreatic fistula, early 
post-pancreatectomy hemorrhage, or bile leak, the drain was left in place. In addition, 
abdominal ultrasound was performed on POD3 and, if this showed a fluid collection > 5 cm, 
the drain was left in place. Presumably, the reason for this additional scrutiny was that, as 
patients resume oral intake in the first few days after surgery, a POPF may become evident. 
A simple, inexpensive, clinically predictive test to reassess the risk of subsequent CR-POPF 
on POD3 would be useful in directing drain removal, since visual appearance of the drain 
may not be a reliable way to assess risk and use of abdominal ultrasound for every patient is 
likely not economically or logistically feasible.
It was hypothesized that a supplemental analysis of DFA on POD3 could add to the value of 
POD1 DFA in providing a clinically useful and more reliable method to predict which 
patients will not develop a CR-POPF. The cut-off of 350 U/L was selected based on the 
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meta-analysis by Giglio et al.3 Data from a prospectively maintained consortium database 
were reviewed retrospectively to determine the association of DFA on POD1 and POD3 with 
postoperative outcomes.
Methods
Analyzed data were reviewed retrospectively from a prospectively maintained Pancreas 
Surgery Registry including three high-volume academic pancreas centers. After obtaining 
informed consent, data were entered prospectively into the database by trained data analysts 
under the supervision of the surgeons. All data were backed up by source documents and the 
accuracy of data entered to the electronic database was periodically reviewed and verified by 
the coordinating center (Baylor College of Medicine).7 Permission for this study was 
obtained from an Institutional Review Board (H-38662).
Although patients who underwent pancreatoduodenectomy (PD) or distal pancreatectomy 
(DP) were included, outcomes for these two different operations were analyzed separately. 
Patients without intraperitoneal drains and without POD1 and 3 DFA data were excluded 
from the study. Patients with POD1 DFA ≤ 5000 U/L were divided into two groups based on 
their POD3 DFA concentration: Group A (≤ 350 U/L) and Group B (> 350 U/L). The 
measurement of DFA on POD1 and POD3 is part of the institutional protocol. In patients 
with multiple drains the highest DFA concentration from any drain was used. Drain removal 
was recorded as the date on which the last drain was removed.
Baseline demographics and comorbidities such as body mass index (BMI), hypertension, 
chronic obstructive pulmonary disease (COPD), peripheral vascular disease, diabetes, 
chronic pancreatitis, renal insufficiency, and smoking history were obtained from the 
database. Perioperative characteristics included pancreatic texture, pancreatic duct size, 
anastomotic technique, pathologic diagnosis, estimated blood loss (EBL), transfusion 
requirement, American Society of Anesthesiologists (ASA) score, and length of procedure. 
Complications within 60 days of surgery were recorded and graded using the Accordion 
Severity Grading for Surgical Complications,8 and the International Study Group of 
Pancreatic Fistula (ISGPF) and the International Study Group of Pancreatic Surgery (ISGPS) 
definitions9–10 for pancreatic fistula and delayed gastric emptying (DGE). A detailed 
definition of complications has been previously reported.8 Patients were followed for 
mortality for 90 days after surgery. The primary outcome of interest was CR-POPF. Chi-
square or Fisher’s exact tests, when appropriate, were used to analyze categorical variables. 
Student’s t-test or Mann-Whitney tests were used to evaluate continuous variables. Simple 
logistic regression analysis was employed to evaluate the ability of POD1 DFA and POD1 in 
combination with POD3 DFA to predict the absence of CR-POPF. A p-value of < 0.05 was 
considered statistically significant. All statistical analyses were performed using SPSS v24 
(IBM Corp. Armonk NY, USA).
Results
Among 687 patients who underwent PD or DP, 380 had intraperitoneal drains placed at the 
time of surgery and had both POD1 and POD3 DFA data available. Fifty-five patients 
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identified with a POD1 DFA > 5000 U/L were analyzed separately. Among the remaining 
325 patients with POD1 DFA ≤ 5000 U/L, 254 patients (78.2%) had a POD3 DFA ≤ 350 
U/L (Group A) and 71 patients (21.8%) had a POD3 DFA > 350 U/L (Group B) (Figure 1). 
241 (74.2%) patients underwent PD and 84 (25.8%) underwent DP. The overall rate of CR-
POPF among patients with POD1 DFA ≤ 5000 U/L was 7.1%.
Among the 55 patients with POD1 DFA > 5000 U/L, 43 (78.2%) underwent PD and 12 
(21.8%) underwent DP. Overall, the median POD1 DFA was 9729 U/L (7330 – 13,108 U/L) 
and median POD3 DFA was 1009 U/L (594 – 3076 U/L). The overall rate of fistula of any 
grade was 85.4% while the rate of CR-POPF was 34.5%. The date of drain removal was 
available for 45 (81.8%) patients in this group. All patients had their intraperitoneal drains 
removed after POD5 (median POD16, IQR POD8-POD29). Among the 43 patients who 
underwent PD, 41(95.3%) had soft gland texture and 37.2% developed a CR-POPF.
Table 1 displays the baseline characteristics of the study population with POD1 DFA ≤ 5000 
U/L. There was no significant difference in age, gender, ethnicity, race, or distribution of 
comorbidities between Group A (POD3 DFA ≤ 350 U/L) and Group B (POD3 DFA > 350 
U/L). There was a difference in the initial diagnosis between the two groups but only in 
patients who underwent PD. Patients in Group B had smaller pancreatic duct diameters, 
were more likely to have soft gland texture, less frequently had a diagnosis of pancreatic 
adenocarcinoma or pancreatitis on final pathology, and had an increased LOS when 
compared with patients in Group A (Table 1). Additionally, there were more ASA class 4 
patients in Group B. When subset analysis was performed based on procedure type, these 
differences persisted in patients undergoing PD but not DP.
Morbidity was greater in Group B. Complications of any grade were more frequent (35 
(49.3%) vs 87 (34.3%), p = 0.021). CR-POPF, the main outcome variable of interest, was 
more frequent in Group B (13 (18.3%) vs 10 (3.9%), p < 0.001). The difference in other 
specific complications did not reach significance. The differences in overall complication 
rate and CR-POPF persisted in patients undergoing PD but not DP (Table 2).
Data on the timing of drain removal were available for 189 (74.4%) patients in Group A and 
45 (63.3%) in Group B. In both groups, most patients had their drains removed late, after 
POD5 (54.5% of patients in Group A and 91.1% in Group B (Figure 2)). The median POD 
of drain removal in Group A was POD6 (4–13) while it was POD11 (7–20) in Group B. 
When the patients in Group A were divided into subgroups according to timing of drain 
removal (early removal: ≤ POD5, late removal: after POD5), morbidity was greater in the 
late drain removal group (Table 3). This difference persisted in subgroup analysis of those 
patients in Group A that did not develop CR-POPF (45 (47.9%) vs 23 (28.8%), p = 0.013).
POD1 DFA alone significantly predicted the absence of CR-POPF. When compared to this 
test, combining POD1 DFA ≤ 5000 U/L and POD3 DFA ≤ 350 U/L, had a higher odds ratio 
for predicting no CR-POPF. This persisted when the tests were used to evaluate the absence 
of CR-POPF in PD and DP.
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Discussion
CR-POPF remains a major concern for pancreatic surgeons. In patients at low risk of a 
pancreatic fistula, increased complications have been reported when removal of drains is 
delayed.1, 11–20 Many surgeons continue to place intraperitoneal drains at the time of surgery 
because these have proven critical in mitigating pancreatic fistulae and associated 
complications. In a randomized controlled trial, Bassi and colleagues showed delayed drain 
removal in patients at low risk of pancreatic fistula was associated with an increased rate of 
pancreatic fistulae and abdominal complications when compared with early drain removal.1 
In this study, late removal was defined as after POD5. Kawai and colleagues also 
demonstrated increased fistula rates and intra-abdominal infections with late removal of 
drains when compared with early removal.19 In this study, late drain removal was defined as 
after POD8. In a Cochrane review, Peng et al. demonstrated that late drain removal was 
associated with higher rates of postoperative complications.15 These studies favor an early 
drain removal strategy to mitigate postoperative complications in patients at low risk of 
developing CR-POPF. Complete elimination of drains, particularly in the setting of 
pancreatoduodenectomy, is not advisable based on available evidence. Mortality has been 
shown to increase fourfold in patients undergoing PD without intraperitoneal drains placed 
at the time of surgery.20 Placement of a drain at the time of resection and early drain removal 
in selected patients at low risk for CR-POPF is an alternative approach. This strategy may 
improve outcomes by having a drain already in place to mitigate a pancreatic fistula if one 
develops, and having the drain removed early (on or before POD5) to eliminate any potential 
harm caused by a drain in patients who do not develop a fistula. Thus, a simple, inexpensive, 
clinically useful objective test in the early postoperative period to assess the risk of 
subsequent CR-POPF would be useful.
Several reports have been published that propose guidelines for drain management based on 
drain fluid characteristics, including POD1 DFA and fluid color/appearance, as well as 
fistula risk scores that incorporate patient-specific intraoperative characteristics, including 
gland texture, duct size, EBL, and pathology.2, 21 Early removal of drains may be safe in 
selected patients at low risk of fistula. In this study, we evaluated the ability of POD3 DFA ≤ 
350, in combination with POD1 DFA ≤ 5000, as a tool to identify which patients will not 
develop a CR-POPF after pancreatectomy. Complications and CR-POPF were more frequent 
in those patients with POD3 DFA > 350. These patients also had smaller pancreatic ducts, 
softer pancreatic texture, and pathological diagnoses that are usually correlated with softer 
gland texture. These factors have been associated with higher rates of pancreatic fistula.11–13 
The combination of POD1 and POD3 DFA may be a simple and clinically useful method to 
identify which patients will not develop a CR-POPF and guide safe early drain removal.
Although the combination of POD1 ≤ 5000 and POD3 ≤ 350 DFA was highly sensitive in 
predicting subsequent CR-POPF, the results must be carefully interpreted. A limitation of 
this retrospective study is that the parameters for drain removal were not controlled. In 
addition to DFA, the color or volume of drain output, the surgeon’s concern about the 
pancreatojejunostomy, pancreatic transection margin, or other factors may have influenced 
decisions about the timing of drain removal.
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The timing of drain removal itself may have been an additional confounding factor. To 
address this, we looked at timing of drain removal in both study groups. Only four patients 
in group B (POD3 DFA > 350 U/L) had drains removed early. In a subset analysis of group 
A (POD3 DFA ≤ 350 U/L) late drain removal (which we defined as after POD5) was 
associated with increased overall morbidity but not with a statistically significant higher rate 
of CR-POPF. Although this data does not prove causality, it is consistent with previous 
reports that have found increased complications with prolonged drain placement after 
pancreatectomy.2, 12–18
When PD and DP subgroups were analyzed separately, overall morbidity and rate of CR-
POPF was higher in patients with POD3 DFA > 350 U/L only in patients undergoing PD. 
Our study may have been underpowered to detect a difference after DP. However, due to the 
different complication profiles of PD and DP it is important to avoid a combined analysis of 
their outcomes.
This study demonstrated that after pancreatectomy, patients at lower risk of CR-POPF 
(POD1 DFA ≤ 5000 U/L) can be further sub-stratified for risk using POD3 DFA ≤ 350. The 
first screen (POD1 DFA) identified about 14% of patients undergoing pancreatectomy that 
would be screened out as high risk for fistula and thus not eligible for early drain removal. 
Using a second screen of POD3 DFA identified an additional 19% at increased risk, thus 
about 1/3 of the patients undergoing pancreatic resection would be screened out of the safe 
early drain removal group. Our data suggests that POD3 DFA may be an additional 
clinically useful guide for surgeons considering early drain removal. However, to prove the 
value of this approach, a randomized prospective trial would be required.
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Figure 1. Patient Selection
Flowchart illustrating patient selection strategy.
IP: intraperitoneal, POD: postoperative day, DFA: drain fluid amylase
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Figure 2. Timing of Drain Removal in Group A and Group B
Figure shows timing of drain removal for Group A and Group B patients as well as the rates 
of CR-POPF with early and late drain removal in each group.
POD: postoperative day, DFA: drain fluid amylase, CR-POPF: clinically relevant 
postoperative pancreatic fistula
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Table 3
Complications and Timing of Drain Removal
Group A Patients with Available Date of Drain Removal Data (n=189)
n (%) Early Drain Removal
(n=86)
Late Drain Removal
(n=103) p-value
Any complications* 24 (27.9%) 51 (49.5%) 0.003
CR-POPF 1 (1.1%) 5 (4.8%) 0.225
Intra-abdominal abscess 2 (2.3%) 9 (8.7%) 0.114
Group B Patients with Available Date of Drain Removal Data (n=45)
n (%) Early Drain Removal
(n=4)
Late Drain Removal
(n=43) p-value
Any complications* 1 (25.0%) 27 (62.7%) 0.286
CR-POPF 1 (25.0%) 9 (20.9%) 0.442
Intra-abdominal abscess 0 3 (6.9%) 1.000
*
Excluding Grade A pancreatic fistula
CR-POPF: clinically relevant postoperative pancreatic fistula
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